Harlem, thanks for your thoughtful reply. I hear you regarding the clout and credibility and certainly the pockets. But then I started thinking about distribution and it seems like we have rather unique requirements there. That got me thinking about training and that’s where my picture blew up in my face. From a treatment standpoint, isn’t this essentially a surgical procedure? Would big pharma really be useful there or am I missing something?
Is it possible that GE Life Sciences might wish to position themselves a bit differently in this new market, taking on a more front-facing role?
News 
Market Data 
Discover 
